Exchange: NYSEArca·Updated 01:38 AM EDT

IWM News

News
all
press releases
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.
Stocktwits
More News
CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead
Morgan Stanley expects investor focus to shift to readouts from the next part of the same trial in patients with severe hypertriglyceridemia due in the back half of the year and other second-half readouts.
Stocktwits
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim.
Stocktwits
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by Novo Nordisk—from its U.S. biologics license application for apitegromab.
Stocktwits
CRML Stock On Track For Best Day In About 4 Months — What’s Driving The Rally?
Critical Metals CEO said in a Bloomberg interview that its rare earth project in Greenland is still on schedule for first production in 2029.
Stocktwits
BULL Stock Eyes Highest Levels In 8 Months — Here's Why Rosenblatt Sees A 67% Upside Potential
According to TheFly, analysts at Rosenblatt maintained their ‘Buy’ rating on Webull and raised their price target to $15 from $13.
Stocktwits
AUPH Stock Rallies 6% After-Hours — Here’s Why
Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.
Stocktwits
AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering
The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.
Stocktwits
Why Is AMLX Stock Popping 14% After Hours?
Amylyx said the company said it will release top-line results from its late-stage trial of blood sugar drug avexitide on Tuesday.
Stocktwits
FTK Clocks Worst Day In Over 6 Years After Wolfpack Research Flags Canceled Deal, Shorts Stock
Wolfpack says the deal made up about 57% of Flotek’s near-term backlog.
Stocktwits

Advertisement|Remove ads.